Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Pulm Pharmacol Ther ; 58: 101819, 2019 10.
Article in English | MEDLINE | ID: mdl-31302339

ABSTRACT

BACKGROUND: ENaC inhibition has been investigated as a CF treatment; however, small molecule inhibitors of ENaC lack efficacy and/or have shown dose-limiting hyperkalemia. SPX-101 is a novel, investigational small peptide (SPLUNC1 mimetic) that regulates ENaC density with the potential for efficacy without systemic effects. METHODS: Two trials are presented: The first was a Phase 1, 2-part, randomized, double-blind, placebo-controlled, ascending-dose study of nebulized SPX-101 in healthy adults. Part 1 evaluated 4 single doses of SPX-101 ranging from 20 to 240 mg. Part 2 evaluated a 14-day regimen of SPX-101 at 4 doses of SPX-101 ranging from 10 to 120 mg BID. Pharmacokinetics, adverse events, spirometry, vital signs, electrocardiograms, pulse oximetry, and clinical laboratory values were assessed. The second trial was a tolerability-confirming, Phase 1b, open-label study conducted in 5 adult subjects with CF. Ascending doses of SPX-101 inhalation solution (10 mg-120 mg BID) were administered for 7 days. Safety was assessed as described above. RESULTS: All 64 healthy volunteers (32 in each Part) completed the single and multiple dose study. SPX-101 was well tolerated with little/no systemic exposure and with no hyperkalemia. Adverse events were generally mild with reported respiratory events associated with the purported pharmacological activity of SPX-101. Tolerability of SPX-101 was similarly observed in adults with CF; all 5 subjects treated with SPX-101 completed the study. CONCLUSIONS: SPX-101 was well-tolerated across a range of doses and had little/no systemic exposure in healthy adults and adults with CF, thus supporting further study in patients with CF. CLINICALTRIAL. GOV REGISTRATION: NCT03056989.


Subject(s)
Cystic Fibrosis/drug therapy , Epithelial Sodium Channel Blockers/pharmacokinetics , Epithelial Sodium Channel Blockers/therapeutic use , Administration, Inhalation , Adult , Dose-Response Relationship, Drug , Double-Blind Method , Epithelial Sodium Channel Blockers/adverse effects , Epithelial Sodium Channels , Female , Glycoproteins/metabolism , Healthy Volunteers , Humans , Male , Middle Aged , Phosphoproteins/metabolism
2.
Curr Opin Pharmacol ; 43: 152-165, 2018 12.
Article in English | MEDLINE | ID: mdl-30340955

ABSTRACT

Cystic fibrosis (CF) is a monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR dysfunction is characterized by abnormal mucociliary transport due to a dehydrated airway surface liquid (ASL) and hyperviscous mucus, among other pathologies of host defense. ASL depletion is caused by the absence of CFTR mediated chloride secretion along with continued activity of the epithelial sodium channel (ENaC) activity, which can also be affected by CFTR mediated anion conductance. Therefore, ENaC has been proposed as a therapeutic target to ameliorate ASL dehydration and improve mucus transport. Inhibition of ENaC has been shown to restore ASL hydration and enhance mucociliary transport in induced models of CF lung disease. To date, no therapy inhibiting ENaC has successfully translated to clinical efficacy, in part due to concerns regarding off-target effects, systemic exposure, durability of effect, and adverse effects. Recent efforts have been made to develop novel, rationally designed therapeutics to produce-specific, long-lasting inhibition of ENaC activity in the airways while simultaneously minimizing off target fluid transport effects, systemic exposure and side effects. Such approaches comprise next-generation small molecule direct inhibitors, indirect channel-activating protease inhibitors, synthetic peptide analogs, and oligonucleotide-based therapies. These novel therapeutics represent an exciting step forward in the development of ENaC-directed therapies for CF.


Subject(s)
Cystic Fibrosis/drug therapy , Epithelial Sodium Channel Blockers/therapeutic use , Epithelial Sodium Channels/drug effects , Lung/drug effects , Mucociliary Clearance/drug effects , Animals , Cystic Fibrosis/genetics , Cystic Fibrosis/metabolism , Cystic Fibrosis/physiopathology , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Diffusion of Innovation , Drug Design , Epithelial Sodium Channel Blockers/adverse effects , Epithelial Sodium Channels/metabolism , Genetic Predisposition to Disease , Humans , Lung/metabolism , Lung/physiopathology , Molecular Targeted Therapy , Mutation , Phenotype , Signal Transduction/drug effects
3.
Bioorg Med Chem Lett ; 25(21): 4797-4801, 2015 Nov 01.
Article in English | MEDLINE | ID: mdl-26235948

ABSTRACT

The design, synthesis and biological evaluation of novel dimeric pyrazinoylguanidines for the treatment of cystic fibrosis (CF) are reported herein. When administered directly to the lung in a guinea pig tracheal potential difference (TPD) model, the dimeric compounds were found to have superior potency, longer duration of action in the lung, and significantly reduced extra-pulmonary exposure in comparison to the corresponding monomeric ENaC blockers, which have been evaluated in the clinic but shown to have dose-limiting kidney toxicity.


Subject(s)
Drug Discovery , Epithelial Sodium Channel Blockers/pharmacology , Epithelial Sodium Channel Blockers/pharmacokinetics , Epithelial Sodium Channels/metabolism , Guanidines/pharmacology , Guanidines/pharmacokinetics , Lung/drug effects , Lung/metabolism , Animals , Dose-Response Relationship, Drug , Epithelial Sodium Channel Blockers/adverse effects , Epithelial Sodium Channel Blockers/chemistry , Guanidines/adverse effects , Guanidines/chemistry , Guinea Pigs , Kidney/drug effects , Molecular Structure , Structure-Activity Relationship
4.
Br J Pharmacol ; 172(11): 2814-26, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25573195

ABSTRACT

BACKGROUND AND PURPOSE: Inhaled amiloride, a blocker of the epithelial sodium channel (ENaC), enhances mucociliary clearance (MCC) in cystic fibrosis (CF) patients. However, the dose of amiloride is limited by the mechanism-based side effect of hyperkalaemia resulting from renal ENaC blockade. Inhaled ENaC blockers with a reduced potential to induce hyperkalaemia provide a therapeutic strategy to improve mucosal hydration and MCC in the lungs of CF patients. The present study describes the preclinical profile of a novel ENaC blocker, NVP-QBE170, designed for inhaled delivery, with a reduced potential to induce hyperkalaemia. EXPERIMENTAL APPROACH: The in vitro potency and duration of action of NVP-QBE170 were compared with amiloride and a newer ENaC blocker, P552-02, in primary human bronchial epithelial cells (HBECs) by short-circuit current. In vivo efficacy and safety were assessed in guinea pig (tracheal potential difference/hyperkalaemia), rat (hyperkalaemia) and sheep (MCC). KEY RESULTS: In vitro, NVP-QBE170 potently inhibited ENaC function in HBEC and showed a longer duration of action to comparator molecules. In vivo, intratracheal (i.t.) instillation of NVP-QBE170 attenuated ENaC activity in the guinea pig airways with greater potency and duration of action than that of amiloride without inducing hyperkalaemia in either guinea pig or rat. Dry powder inhalation of NVP-QBE170 by conscious sheep increased MCC and was better than inhaled hypertonic saline in terms of efficacy and duration of action. CONCLUSIONS AND IMPLICATIONS: NVP-QBE170 highlights the potential for inhaled ENaC blockers to exhibit efficacy in the airways with a reduced risk of hyperkalaemia, relative to existing compounds.


Subject(s)
Amiloride/analogs & derivatives , Amiloride/pharmacology , Epithelial Cells/drug effects , Epithelial Sodium Channel Blockers/pharmacology , Hyperkalemia/chemically induced , Mucociliary Clearance/drug effects , Phenyl Ethers/pharmacology , Piperidines/pharmacology , Administration, Inhalation , Amiloride/adverse effects , Animals , Epithelial Sodium Channel Blockers/adverse effects , Guanidines , Guinea Pigs , In Vitro Techniques , Phenyl Ethers/adverse effects , Piperidines/adverse effects , Pyrazines , Rats , Respiratory Mucosa/cytology , Sheep
5.
J Aerosol Med Pulm Drug Deliv ; 27(3): 200-8, 2014 Jun.
Article in English | MEDLINE | ID: mdl-23905576

ABSTRACT

BACKGROUND: Inhaled epithelial sodium channel (ENaC) blockers are designed to increase airway surface liquid volume, thereby benefiting cystic fibrosis patients. This study evaluated the safety, tolerability, and pharmacokinetics of multiple doses of ENaC blocker GS-9411, in healthy participants. METHODS: This randomized, double-blind, placebo-controlled, parallel-group, residential, Phase 1 study evaluated inhaled GS-9411 (2.4, 4.8, and 9.6 mg) or placebo, dosed twice daily for 14 days. RESULTS AND CONCLUSIONS: GS-9411 was well tolerated; 86.1% of treated participants completed dosing (n=31/36). Cough and dizziness (27.8% participants each; most of mild severity) were the most commonly reported adverse events and occurred in both placebo and GS-9411 treatment groups. Arrhythmias were not observed for GS-9411-treated participants, and electrocardiographic changes were not considered clinically significant. Serum potassium levels exceeded the upper limit of normal (>5 mmol/L), 4 hr after the morning dose in GS-9411 (n=16/24) and placebo (n=4/12) treatment groups (38 incidences total). Retesting revealed levels had returned to normal within 2-3 hr. In urine electrolyte analyses, obtained 0-6 hr after the Day 1 morning dose, mean sodium/potassium ratios significantly increased from values 0-6 hr before dosing. Increased urine sodium/potassium ratios corresponded with high urine concentrations of active GS-9411 metabolites, which inhibited sodium reabsorption in the kidney, leading to the observed transient hyperkalemia in these participants. Inhaled GS-9411 was well tolerated except for the emergence of transient clinically significant hyperkalemia; this finding resulted in termination of further clinical development of this drug and will necessitate development of a new generation of ENaC blockers, which provide a sustained improvement in mucociliary clearance, while reducing renal exposure to ENaC blockade. Transient increases in mean urine sodium/potassium ratios appeared to be the first signal of electrolyte imbalances resulting from drug-induced block of ENaC in the kidney. The results of this study strongly suggest that clinical trials of novel ENaC blockers will require intensive measurement of plasma and urine electrolyte levels.


Subject(s)
Epithelial Sodium Channel Blockers/administration & dosage , Epithelial Sodium Channel Blockers/adverse effects , Hyperkalemia/chemically induced , Potassium/blood , Acute Disease , Administration, Inhalation , Adult , Australia , Biomarkers/blood , Biomarkers/urine , Double-Blind Method , Drug Administration Schedule , Epithelial Sodium Channel Blockers/pharmacokinetics , Female , Healthy Volunteers , Humans , Hyperkalemia/blood , Hyperkalemia/diagnosis , Hyperkalemia/urine , Male , Potassium/urine , Risk Assessment , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...